As of Mar 24
| +0.15 / +1.12%|
The 9 analysts offering 12-month price forecasts for Momenta Pharmaceuticals Inc have a median target of 17.00, with a high estimate of 30.00 and a low estimate of 6.00. The median estimate represents a +25.46% increase from the last price of 13.55.
The current consensus among 9 polled investment analysts is to Hold stock in Momenta Pharmaceuticals Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.